Physician profile
Brian R Johnson
NPI 1588872410
$10,641.69
in general payments reported to CMS, 2019-2025
28 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,511 · 2020: $566 · 2021: $1,822 · 2022: $855 · 2023: $1,114 · 2024: $1,239 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,886.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,384.10 | 2019-2025 | Clareon, Unity, Lensx |
| Johnson & Johnson Surgical Vision, INC. | $2,306.66 | 2019-2021 | |
| Allergan, INC. | $480.49 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $451.80 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $345.98 | 2022-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Rayner Intraocular Lenses Limited | $286.09 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Sight Sciences, INC. | $271.62 | 2021-2024 | Omni Surgical System, Tearcare System |
| Rxsight INC | $269.79 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Abbvie INC. | $261.33 | 2022-2025 | |
| Oyster Point Pharma, INC. | $237.24 | 2023-2025 | Tyrvaya |
| Glaukos Corporation | $218.40 | 2019-2021 | |
| Ocular Therapeutix, INC. | $167.67 | 2020-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $162.09 | 2019-2022 | |
| Ivantis, INC | $161.11 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $117.28 | 2024-2025 | Xdemvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $102.86 | 2023 | Acthar |
| Sun Pharmaceutical Industries INC. | $94.98 | 2023-2025 | Cequa |
| Biotissue Holdings INC. | $59.71 | 2023 | |
| Shire North American Group INC | $40.95 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $39.24 | 2021 | |
| Harrow Eye, LLC | $35.89 | 2024 | Vevye |
| Orthofix Medical, INC. | $29.20 | 2023 | Trinity Elite |
| Thea Pharma INC. | $24.68 | 2023 | Iyuzeh |
| Dompe US, INC. | $21.45 | 2025 | Oxervate |
| Omeros Corporation | $19.68 | 2020 | |
| Eyepoint US, INC. | $18.49 | 2019 | |
| Amgen INC. | $17.84 | 2024 | Tepezza |
| Boston Scientific Corporation | $15.07 | 2023 | Ekosonic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.